BeOne Congress Central
2025 ASCO® Annual Meeting May 30 - June 3, 2025 McCormick Place | Chicago, IL & Online
2025 ASCO® Annual Meeting May 30 - June 3, 2025 McCormick Place | Chicago, IL & Online
McCormick Place | Chicago
Hall A1, South Building
Saturday, May 31-Monday, June 2
9:00 AM to 5:00 PM CDT
The contents of the presentations below are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
Want to receive the latest news on BeOne’s congress activities, pipeline, data, and more?
| Type | Title | Presenting Author |
|---|---|---|
| Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results from SEQUOIA Arm D | Mazyar Shadman | |
| ONLINE PUBLICATION | A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL) | Mazyar Shadman |
| POSTER | A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors: First disclosure of clinical data | Rohit Joshi |
| POSTER | First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase | Cesar A. Perez |
| ONLINE PUBLICATION | Adverse events of interest (AEIs) of zanubrutinib vs. fixed-duration combination of venetoclax and obinutuzumab in treatment-naïve (TN) chronic lymphocytic leukemia (CLL) | Wassim Aldairy |
| SEQUOIA 5-year follow-up of Arm C: Frontline zanubrutinib monotherapy in del(17p) patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) | Constantine S. Tam | |
| POSTER | Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)-guided neoadjuvant (n) treatment for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis | Longqi Chen |
| POSTER | Final analysis of multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients (pts) with selected solid tumors | Keun-Wook Lee |
| ONLINE PUBLICATION | Efficacy of continuous zanubrutinib vs. fixed duration venetoclax in combination with obinutuzumab in treatment-naïve (TN) chronic lymphocytic leukemia (CLL): A matching-adjusted indirect comparison (MAIC) | Talha Munir |
| ONLINE PUBLICATION | Real-world zanubrutinib treatment patterns in mantle cell lymphoma (MCL) among US community oncology patients with prior Bruton tyrosine kinase inhibitor (BTKi) therapy | Rushir Choksi |
| ONLINE PUBLICATION | Real-world zanubrutinib treatment patterns in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) among US community oncology patients with prior acalabrutinib therapy | Jing-Zhou Hou |
| ONLINE PUBLICATION | Real-world Bruton tyrosine kinase inhibitor (BTKi) use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) | Jing-Zhou Hou |
| ONLINE PUBLICATION | Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia (CLL) | Adam S. Kittai |
| ONLINE PUBLICATION | Real-world comparative effectiveness of first-line Bruton tyrosine kinase inhibitors (BTKis) in patients with chronic lymphocytic leukemia (CLL) | Ryan Jacobs |
| ONLINE PUBLICATION | Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and treated with covalent Bruton tyrosine kinase inhibitors (cBTKi): A real-world study | Ayad K. Ali |
| ONLINE PUBLICATION | Comparing real-world treatment patterns and outcomes of zanubrutinib and acalabrutinib in CLL/SLL at University of California academic health centers | Aryan Ayati |
| ONLINE PUBLICATION | Comparative efficacy of zanubrutinib (ZANU) versus fixed-duration acalabrutinib plus venetoclax (AV) for first-line treatment of chronic lymphocytic leukemia (CLL): A matching-adjusted indirect comparison (MAIC) | Talha Munir |
| ONLINE PUBLICATION | Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) Bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): Age-related disparity | Keri Yang |
| ONLINE PUBLICATION | Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared to those treated with zanubrutinib: A real-world study | Jamie Colasurdo |
| POSTER | Treatment preferences of patients, caregivers, and physicians in follicular lymphoma (FL): A global discrete-choice experiment (DCE) study | Mitchell Smith |
| POSTER | Lung cancer enrollment of demographic subgroups in US clinical trial sites | Caroline Der-Nigoghossian |
| POSTER | A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC or NPC | Min Hee Hong |
| ONLINE PUBLICATION | A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies | Tae Min Kim |
Type:
Title: Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results from SEQUOIA Arm D
Presenting Author: Mazyar Shadman
Type: ONLINE PUBLICATION
Title: A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL)
Presenting Author: Mazyar Shadman
Type: POSTER
Title: A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors: First disclosure of clinical data
Presenting Author: Rohit Joshi
Type: POSTER
Title: First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase
Presenting Author: Cesar A. Perez
Type: ONLINE PUBLICATION
Title: Adverse events of interest (AEIs) of zanubrutinib vs. fixed-duration combination of venetoclax and obinutuzumab in treatment-naïve (TN) chronic lymphocytic leukemia (CLL)
Presenting Author: Wassim Aldairy
Type:
Title: SEQUOIA 5-year follow-up of Arm C: Frontline zanubrutinib monotherapy in del(17p) patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Presenting Author: Constantine S. Tam
Type: POSTER
Title: Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)-guided neoadjuvant (n) treatment for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis
Presenting Author: Longqi Chen
Type: POSTER
Title: Final analysis of multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients (pts) with selected solid tumors
Presenting Author: Keun-Wook Lee
Type: ONLINE PUBLICATION
Title: Efficacy of continuous zanubrutinib vs. fixed duration venetoclax in combination with obinutuzumab in treatment-naïve (TN) chronic lymphocytic leukemia (CLL): A matching-adjusted indirect comparison (MAIC)
Presenting Author: Talha Munir
Type: ONLINE PUBLICATION
Title: Real-world zanubrutinib treatment patterns in mantle cell lymphoma (MCL) among US community oncology patients with prior Bruton tyrosine kinase inhibitor (BTKi) therapy
Presenting Author: Rushir Choksi
Type: ONLINE PUBLICATION
Title: Real-world zanubrutinib treatment patterns in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) among US community oncology patients with prior acalabrutinib therapy
Presenting Author: Jing-Zhou Hou
Type: ONLINE PUBLICATION
Title: Real-world Bruton tyrosine kinase inhibitor (BTKi) use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Presenting Author: Jing-Zhou Hou
Type: ONLINE PUBLICATION
Title: Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia (CLL)
Presenting Author: Adam S. Kittai
Type: ONLINE PUBLICATION
Title: Real-world comparative effectiveness of first-line Bruton tyrosine kinase inhibitors (BTKis) in patients with chronic lymphocytic leukemia (CLL)
Presenting Author: Ryan Jacobs
Type: ONLINE PUBLICATION
Title: Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and treated with covalent Bruton tyrosine kinase inhibitors (cBTKi): A real-world study
Presenting Author: Ayad K. Ali
Type: ONLINE PUBLICATION
Title: Comparing real-world treatment patterns and outcomes of zanubrutinib and acalabrutinib in CLL/SLL at University of California academic health centers
Presenting Author: Aryan Ayati
Type: ONLINE PUBLICATION
Title: Comparative efficacy of zanubrutinib (ZANU) versus fixed-duration acalabrutinib plus venetoclax (AV) for first-line treatment of chronic lymphocytic leukemia (CLL): A matching-adjusted indirect comparison (MAIC)
Presenting Author: Talha Munir
Type: ONLINE PUBLICATION
Title: Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) Bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): Age-related disparity
Presenting Author: Keri Yang
Type: ONLINE PUBLICATION
Title: Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared to those treated with zanubrutinib: A real-world study
Presenting Author: Jamie Colasurdo
Type: POSTER
Title: Treatment preferences of patients, caregivers, and physicians in follicular lymphoma (FL): A global discrete-choice experiment (DCE) study
Presenting Author: Mitchell Smith
Type: POSTER
Title: Lung cancer enrollment of demographic subgroups in US clinical trial sites
Presenting Author: Caroline Der-Nigoghossian
Type: POSTER
Title: A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC or NPC
Presenting Author: Min Hee Hong
Type: ONLINE PUBLICATION
Title: A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies
Presenting Author: Tae Min Kim
Our proposed name change to BeOne Medicines reaffirms our commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible.
Test Before Treat, a campaign from the CLL Society that is powered by BeOne, empowers people living with CLL and SLL by educating on the importance of biomarker testing and testing before treatment to ensure more informed treatment decisions are possible. Testing patients before initiating any CLL treatment can provide a better understanding of biomarkers and mutations, significantly improving the treatment journey and future disease trajectory for patients.
CLL=chronic lymphocytic leukemia; SLL=small lymphocytic lymphoma.
LEARN MORE ABOUT OUR APPROVED BTK INHIBITOR
LEARN MORE ABOUT OUR APPROVED PD-1 INHIBITOR
BeOne’s R&D APPROACH
